Pandorum Technologies, Nucelion Therapeutics Partner On Exosome-Based Ocular Regenerative Therapy

 

Pandorum Technologies, a clinical-stage regenerative medicine company, on Tuesday announced a strategic collaboration with Hyderabad-based Nucelion Therapeutics, a specialised contract research, development and manufacturing organisation (CRDMO), to expand manufacturing capabilities for Pandorum’s exosome-based therapeutic platform across the Asia-Pacific (APAC) region.

The strategic collaboration aligns with a shared vision, as Pandorum's assets progress toward clinical trials, said a joint press release from the companies.

 

"By leveraging Nucelion Therapeutics’ manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward. Furthermore, it reaffirms India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world," it said.

 

Tuhin Bhowmick, Co-Founder and Chief Executive Officer, Pandorum Technologies, said Pandorum is building a global regenerative medicine platform designed for scale, consistency, and partnership. "As our programs advance toward clinical and commercial milestones, establishing robust, regionally aligned manufacturing infrastructure is a strategic priority," he said. Bhowmick said Nucelion Therapeutics brings strong expertise in advanced biologics manufacturing and a high-quality operational environment that aligns well with Pandorum Technologies' long-term vision of delivering programmable exosome therapies to patients worldwide.

 

Raghu Malapaka, Chief Business Officer, Nucelion Therapeutics, said they were pleased to partner with Pandorum Technologies on the development of Kuragenx, an innovative exosome-based therapy with the potential to redefine the treatment paradigm for ocular diseases. "Our advanced manufacturing platforms and quality systems are designed to support complex biologics, and we look forward to enabling the scalable production of Pandorum’s designer exosome-based assets for patients across the APAC region," he said. Jitendra Kumar, Managing Director, BIRAC, Dept of Biotechnology, Government of India, said the strategic collaboration of Pandorum and Nucelion to manufacture advanced therapeutics sends out an "important signal towards the readiness of both Innovate and Make in India, for addressing unmet global clinical needs". While the current programs span ocular surface injury and inflammatory corneal diseases, including Stevens–Johnson syndrome (SJS), Neurotrophic Keratitis, Pandorum plans to expand its disease-modifying treatments to reverse degenerative changes of skin, pulmonary, and other organ systems, affected by inflammation, vascular pathologies and fibrosis.